March 5, 2009Recalls and Safety Alerts: Higher Mortality for Certain Elderly Patients with Innohep Recalls and Safety Alerts: Higher Mortality for Certain Elderly Patients with Innohep
Celgene is alerting healthcare professionals of an increased mortality risk among certain elderly patients treated with Innohep (tinzaparin sodium injection). Innohep is a low-molecular weight heparin that is used along with warfarin to treat acute ... Source: www.accessdata.fda.gov March 2009 Patient Safety News Video news show for healthcare professionals, covering safety alerts, recalls, product approvals, and important tips on protecting patients. Source: www.fda.gov CDER Organization Charts CDER Organization Charts (updated) Source: www.fda.gov BPCA/Pediatric Exclusivity Statistics BPCA/Pediatric Exclusivity Statistics (updated) Source: www.fda.gov Drug Safety Oversight Board Meetings Memorandum of Meeting Minutes, Drug Safety Oversight Board Meeting, January 15, 2009 Source: www.fda.gov Guidance for Industry New Revised/Withdrawn List for 2009 Source: www.fda.gov CellCept (mycophenolate mofetil) Medication Guide issued, providing important safety information, to be distributed to every patient who fills a CellCept prescription from this point forward. Source: www.fda.gov Metoclopramide-Containing Drugs Chronic use of metoclopramide has been linked to tardive dyskinesia, which may include involuntary and repetitive movements of the body, even after the drugs are no longer taken. Source: www.fda.gov Raptiva (efalizumab) Public Health Advisory describes rare brain condition, progressive multifocal leukoencephalopathy, associated with the use of Raptiva. Source: www.fda.gov # posted by Network @ 8:37 PM
 |
Subscribe to Posts [Atom]